Citation Impact
Citing Papers
DARPP-32 knockout mice exhibit impaired reversal learning in a discriminated operant task
2000 StandoutNobel
Parkinson disease
2017 Standout
Parkinson's disease
2021 Standout
How to diagnose MSA early: the role of magnetic resonance imaging
2005
Bruxism physiology and pathology: an overview for clinicians*
2008 Standout
National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach
2011 Standout
Calcium, ageing, and neuronal vulnerability in Parkinson's disease
2007
Parkinson’s Disease as a Disconnection Syndrome
2010
Parkinson's disease: clinical features and diagnosis
2008 Standout
Staging of brain pathology related to sporadic Parkinson’s disease
2002 Standout
Drug Addiction and Its Underlying Neurobiological Basis: Neuroimaging Evidence for the Involvement of the Frontal Cortex
2002 Standout
Stages in the development of Parkinson’s disease-related pathology
2004 Standout
Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)
2004
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
2007 Standout
Epidemiology of Parkinson's disease
2006 Standout
In vivo imaging of synaptic function in the central nervous system
2009
Comparison of diffusion‐weighted imaging and [123I]IBZM‐SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease
2004
Epidemiology of Parkinson’s disease
2017 Standout
Low Level of Brain Dopamine D2 Receptors in Methamphetamine Abusers: Association With Metabolism in the Orbitofrontal Cortex
2001 Standout
Parkinson's disease
2015 Standout
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
2011 Standout
Pathophysiological distortions in time perception and timed performance
2011 Standout
A distributional code for value in dopamine-based reinforcement learning
2020 StandoutNatureNobel
Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy
2007
Where Does Parkinson Disease Pathology Begin in the Brain?
2002
Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia
1992
Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia
2000 Standout
Directed evolution of a magnetic resonance imaging contrast agent for noninvasive imaging of dopamine
2010 StandoutNobel
The epidemiology of Parkinson's disease: risk factors and prevention
2016 Standout
Transmembrane Signalling Systems in the Brain of Patients with Parkinson's Disease
1993
Low cerebrovascular reserve capacity in long-term follow-up after subarachnoid hemorrhage
2005
Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand
2002
International Union of Pharmacology. XLVII. Nomenclature and Structure-Function Relationships of Voltage-Gated Sodium Channels
2005 Standout
The diagnosis of Parkinson's disease
2005
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
2003 Standout
Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine
1999
Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography
1992
Epidemiology of Bruxism in Adults: A Systematic Review of the Literature
2013 Standout
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
2012 Standout
Diagnosis and Treatment of Parkinson Disease
2020 Standout
Preclinical (premotor) Parkinson’s disease
2000
Dopamine D2 Receptor Blockade and Antimigraine Action of Flunarizine
1994
MDS clinical diagnostic criteria for Parkinson's disease
2015 Standout
Striatal D2 Receptor Binding in Sleep Bruxism: A Controlled Study with Iodine-123-Iodobenzamide and Single-photon-emission Computed Tomography
1996
Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study
1993
Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective
2016
Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort
2012
Importance of low diagnostic Accuracy for early Parkinson's disease
2018
Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage
2012 Standout
Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT.
1994
Applications of Clinical Dopamine Imaging
2006
Association of Dopamine Transporter Reduction With Psychomotor Impairment in Methamphetamine Abusers
2001
Differential Inhibition of T-Type Calcium Channels by Neuroleptics
2002
Second consensus statement on the diagnosis of multiple system atrophy
2008 Standout
Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society.
1997 Standout
Rotenone, Paraquat, and Parkinson’s Disease
2011 Standout
Works of S. Wenger being referenced
Dopamine D2 Receptor Imaging with SPECT: Studies in Different Neuropsychiatric Disorders
1991
A study of acetazolamide-induced changes in cerebral blood flow using99mTc HMPAO SPECT in patients with cerebrovascular disease
1995
Dopamine D2 receptor imaging and measurement with SPECT.
1993
Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
1997
D2 Receptor Blockade by Flunarizine and Cinnarizine Explains Extrapyramidal Side Effects. A SPECT Study
1995
Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease.
1997
Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease.
1997